MICHELLE A FANALE to Lymphoma, B-Cell
This is a "connection" page, showing publications MICHELLE A FANALE has written about Lymphoma, B-Cell.
Connection Strength
0.579
-
Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018 06 12; 2(11):1334-1343.
Score: 0.094
-
Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun; 169(6):814-23.
Score: 0.076
-
Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. Lancet Haematol. 2015 Apr; 2(4):e166-74.
Score: 0.076
-
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014 Oct; 167(2):177-84.
Score: 0.072
-
Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901.
Score: 0.072
-
Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment? Hematology Am Soc Hematol Educ Program. 2013; 2013:406-13.
Score: 0.065
-
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol. 2012 Aug 01; 30(22):2776-82.
Score: 0.063
-
TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood. 2012 Aug 23; 120(8):1613-23.
Score: 0.062